And...
https://www.biospace.com/article/pfizer-triple-partners-for-future-mrna-vaccines-and-genetic-medicinesPfizer Triple-Partners for Future mRNA Vaccines and Genetic Medicines - Published: January 10, 2022The COVID-19 pandemic has brought to light the incredible power of collaboration in the life science industry. Together, we get more done. Around 40% of Pfizer’s portfolio was realized through partnerships, and Monday, the pharma giant announced three more collaborative deals.
Pfizer’s current spotlight, of course, is from its mRNA vaccine in the fight against the novel coronavirus. Developed in collaboration with Germany’s BioNTech, Comirnaty was the very first COVID-19 vaccine approved by the FDA.
The Pfizer-BioNTech vaccine already uses Acuitas Therapeutics’ lipid nanoparticle technology. With a new agreement struck between the companies, Pfizer will “harness the power of the mRNA-LNP technology and deliver potential new breakthrough vaccines and therapeutics that address significant unmet needs for patients,” CSO and President of Worldwide R&D Mikael Dolsten said. The company plans to explore more projects in its existing vaccine areas and expand to new areas using the tech...
Historically, Pfizer played a pivotal role in eradicating polio and smallpox. Current programs focus on preventing pneumococcal disease, influenza, RSV, Lyme disease, and more childhood, adolescent, and adult infections. The company shows 17 vaccine projects in the pipeline.
Vaccines, once thought of as the red-headed stepchild compared to more lucrative drugs that require daily doses, have shot up in recent years with a few blockbuster vaccines like the one administered to prevent HPV. COVID-19 has swung the numbers wildly to the other side, with Pfizer expecting to make nearly as much from its vaccines in 2021 as it earned in total in 2020. Indeed, vaccines have become a lucrative industry, thanks to a global pandemic.